Clinical trial · Observational
Strain Imaging in Breast Cancer Patients Receiving Trastuzumab
NCT02080390CI-TRIAL-00037404completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart. Trastuzumab (Herceptin) is used to treat specific types of breast cancer and is known to cause weakening of the heart. Unfortunately, little is know as to why this this happens. The investigators want to identify any factors that may lead to the early detection, treatment and prevention of the cardiotoxicity (heart problem) associated with this drug.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Her 2 Positive Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transthoracic echocardiogram (ultrasound) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Transthoracic echocardiogram (ultrasound)
- description
- Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
- interventionNames
- Procedure: Transthoracic echocardiogram (ultrasound)
Primary outcomes (2)
- measure
- Longitudinal Strain
- timeFrame
- Change in baseline longitudinal strain from beginning of study to end of study. Patients will be followed for a minimum of 1 year.
- description
- Each transthoracic echocardiogram obtained during the patient's treatment will be assessed for longitudinal strain.
- measure
- Left Ventricular Ejection Fraction
- timeFrame
- Change in ejection fraction from baseline to end of study. Patients will be followed for a minimum of 1 year.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than 18 years * Her 2 positive breast cancer. * Patients who are currently receiving Trastuzumab (Herceptin). * Patients who received Trastuzumab (Herceptin) after the formation of the UFHealth Medical Plaza pharmacy database was initiated. Exclusion Criteria: * Age less than 18 years * Patients who have not received Trastuzumab (Herceptin). * Patients who received Trastuzumab prior to the formation of the UFHealth Medical Plaza pharmacy database.
References
Publications (0)
Data not yet available
No reference posted for this study.